Journal Home
Search for

Volume 90, Issue 4, Pages 1155-1160 (October 2008)


View previous. 35 of 107 View next.

Association of the protein Z intron F G79A gene polymorphism with recurrent pregnancy loss

Astrid Dossenbach-Glaninger, M.D.a, Michael van Trotsenburg, M.D.b, Hanns Helmer, M.D.c, Christian Oberkanins, Ph.D.d, Pierre Hopmeier, M.D.aCorresponding Author Informationemail address

Received 20 June 2007; received in revised form 25 July 2007; accepted 25 July 2007. published online 04 January 2008.

Objective

To investigate the association of the common protein Z (PZ) intron F G79A gene polymorphism with recurrent early pregnancy loss (RPL) and its gene-gene interaction with known thrombophilic risk factors for RPL.

Design

Case control study.

Setting

University clinic.

Patient(s)

We enrolled 49 women with a history of two consecutive or three to six nonconsecutive pregnancy losses between the 8th and 12th weeks of gestation and 48 age-matched parous controls without a history of pregnancy complications.

Intervention(s)

None.

Main Outcome Measure(s)

Allele frequencies of the PZ intron F G79A polymorphism and its gene-gene interaction with known risk factors for RPL.

Result(s)

Fourteen case subjects (28.6%) and 24 control subjects (50.0%) carried at least one A allele. This was associated with a significant reduction of the relative risk for recurrent pregnancy loss (odds ratio [OR] 0.4, 95% confidence interval [CI] 0.2–0.9; adjusted OR 0.3, 95% CI 0.1–0.8). Coexistence of any thrombophilic risk factor studied with the 79A allele resulted in a clear reduction of the primal relative risk for recurrent pregnancy loss.

Conclusion(s)

The isolated presence of the PZ intron F 79A allele as well as the combination with known thrombophilic risk factors was protective against RPL between the 8th and 12th weeks of gestation.

a Department of Laboratory Medicine, Rudolfstiftung Hospital, Vienna, Austria

b Division of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Vienna, Austria

c Division of Obstetrics and Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

d ViennaLab Diagnostics, Vienna, Austria

Corresponding Author InformationReprint requests: Pierre Hopmeier, M.D., Department of Laboratory Medicine, Rudolfstiftung Hospital, Juchgasse 25, A-1030 Vienna, Austria (FAX: +43 1 71165 3309).

 Supported by Roche Diagnostics, Mannheim, Germany.

 Presented at the 6th International Symposium on Molecular Diagnostics in Laboratory Medicine and 3rd International Symposium on Gene Therapy, May 25–27, 2006, Graz, Austria.

 Dr. Oberkanins is an employee of ViennaLab Diagnostics.

PII: S0015-0282(07)03021-X

doi:10.1016/j.fertnstert.2007.07.1376


View previous. 35 of 107 View next.